Bank of America Corp DE Trims Holdings in Repligen Co. (NASDAQ:RGEN)

Bank of America Corp DE trimmed its stake in Repligen Co. (NASDAQ:RGEN) by 36.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 277,947 shares of the biotechnology company’s stock after selling 158,404 shares during the period. Bank of America Corp DE owned about 0.50% of Repligen worth $40,008,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Moody National Bank Trust Division increased its stake in Repligen by 10.2% during the 4th quarter. Moody National Bank Trust Division now owns 1,591 shares of the biotechnology company’s stock worth $229,000 after buying an additional 147 shares during the period. Park Avenue Securities LLC increased its position in shares of Repligen by 24.8% in the 4th quarter. Park Avenue Securities LLC now owns 3,901 shares of the biotechnology company’s stock valued at $561,000 after purchasing an additional 776 shares during the last quarter. Integrated Investment Consultants LLC increased its position in shares of Repligen by 6.0% in the 4th quarter. Integrated Investment Consultants LLC now owns 2,360 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 134 shares during the last quarter. Artemis Investment Management LLP increased its position in shares of Repligen by 18.4% in the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock valued at $22,143,000 after purchasing an additional 23,905 shares during the last quarter. Finally, Diversify Wealth Management LLC increased its position in shares of Repligen by 74.2% in the 4th quarter. Diversify Wealth Management LLC now owns 3,342 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 1,423 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Thursday, May 8th. Canaccord Genuity Group lowered their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. Finally, TD Cowen initiated coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.25.

Repligen Trading Down 3.7%

Shares of Repligen stock opened at $123.26 on Friday. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $6.92 billion, a P/E ratio of -241.69, a PEG ratio of 4.54 and a beta of 1.21. The company’s fifty day moving average is $133.15 and its two-hundred day moving average is $145.12.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same quarter last year, the business earned $0.28 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.